Clenbuterol

CuraSen Therapeutics to Present Phase 2 Data Showing Rapid-Onset Cognition and Mood Benefit with CST-103/CST-107 (Clenbuterol/Nadolol) in Parkinson’s Disease at the Alzheimer’s Disease and Parkinson’s Disease (AD/PD’23) Conference

Retrieved on: 
Thursday, March 30, 2023
Science, Neurology, Biotechnology, Research, Pharmaceutical, Health, Mental Health, Clinical Trials, Cognition, Clenbuterol, Tremor, International, Depression, PD, Cerebral peduncle, Neurodegenerative disease, Nadolol, Deficit spending, Brain, MCI, Doctor of Philosophy, CNS, Pain, Phase 1, MRI, Arousal, Dysautonomia, HIV disease progression rates, Patient, Pharmacokinetics, Rigidity, Locus coeruleus, Diagnosis, Therapy, Sleep, Memory, Treatment, Pharmaceutical industry

Additionally, the company will present promising Phase 1 data with a second program, CST-2032/CST-107, in healthy participants and patients with mild cognitive impairment (MCI).

Key Points: 
  • Additionally, the company will present promising Phase 1 data with a second program, CST-2032/CST-107, in healthy participants and patients with mild cognitive impairment (MCI).
  • Data will be shared in two oral presentations at the International Alzheimer’s Disease and Parkinson’s Disease (AD/PD’23) conference, being held March 28 - April 1, 2023, in Gothenburg, Sweden.
  • The Phase 2 trial was an exploratory, randomized, double-blinded, crossover study in 25 patients with Parkinson’s disease with cognitive deficits.
  • The trial is taking place at 20 centers in the U.S. and New Zealand, with results anticipated later in 2023.

CuraSen Therapeutics Presents Phase 1b Clinical Data with CST-103 Demonstrating Significant Increases in Cerebral Blood Flow in Patients with Mild Cognitive Impairment or Parkinson’s Disease

Retrieved on: 
Tuesday, November 9, 2021
Biotechnology, Mental Health, Health, Pharmaceutical, Clinical Trials, Neurodegeneration, Government budget balance, Cognition, LC, Hippocampus, Safety, Maintenance, Neuron, Parkinson's disease, Circulator, Therapy, MD, Even and odd functions, Perfusion, KUMC, Palpitations, Doctor of Philosophy, Â, Locus coeruleus, Amygdala, Arousal, Patient, Tremor, Research, RBD, Memory, Central nervous system, Thalamus, Heart rate, Clenbuterol, Brain, Pharmaceutical industry, Medical imaging

Eight patients with mild cognitive impairment or Parkinsons disease were administered a single 80 g (microgram) dose of CST-103.

Key Points: 
  • Eight patients with mild cognitive impairment or Parkinsons disease were administered a single 80 g (microgram) dose of CST-103.
  • Patients who received the initial dose of CST-103 showed significant increases in cerebral blood flow in multiple areas of the brain, including the hippocampus.
  • Increases in cerebral blood flow were consistent one week later in patients who received a second dose of CST-103 as monotherapy.
  • The trials include patients with mild cognitive impairment, Parkinsons disease with rapid eye movement sleep disorder (RBD), Lewy body dementia, and mild cognitive impairment or mild dementia due to either Parkinson's or Alzheimers disease.